Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: October 2009

5 - Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen: Pharmacology for the Future

from SECTION I - Pain Physiology and Pharmacology

REFERENCES

1. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: metaanalysis of randomized trials. JAMA. 2006;296(13):1619–1632.
2. Roberts LJ. Comparative metabolism and fate of the eicosanoids. In: Willis AL, ed. Handbook of Eicosanoids, Prostaglansins and Related Lipids. Boca Raton, FL: CRC Press, 1987:233–244.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235.
4. Cousins MJ. John J. Bonica distinguished lecture: acute pain and the injury response: immediate and prolonged effects. Reg Anesth. 1989;14(4):162–179.
5. Jurna I, Brune K. Central effect of the non-steroid anti-inflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in C fibre-evoked activity in single neurones of the rat thalamus. Pain. 1990;41(1):71–80.
6. Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. [Review] [112 refs] Current Pharmaceutical Design. 10(6):589–601, 2004.
7. Chen LC, Elliott RA, Ashcroft DM. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. [Review] [49 refs] Journal of Clinical Pharmacy & Therapeutics. 29(3):215–29, 2004 Jun.
8. Romsing J, Moiniche S. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. [See comment]. [Review] [58 refs] Acta Anaesthesiologica Scandinavica. 48(5):525–46, 2004.
9. Anderson BJ, Pons G, Autret-Leca E, Allegart K, Boccard E. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Pediatr Anesthes. 2005;15(4):282–292.
10. Hersh EV, Lally ET, Moore PA. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?. [Review] [89 refs] Current Medical Research & Opinion. 21(8):1217–26, 2005 Aug.
11. Graham GG, Scott KF. Mechanism of action of paracetamol. [Article]. Am J Therapeut. 2005;12(1):46–55.
12. Pini LA, Sandrini M, Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol. 1996;308(1):31–40.
13. Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat. Acta Anaesthesiol Scand Suppl. 1995;103:1–44.
14. Bjorkman R, Hallman KM, Hedner J, Hedner T, Henning M. Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P. Pain. 1994;57(3):259–264.
15. Peduto VA, Ballabio M, Stefanini S. Efficacy of propacetamol in the treatment of postoperative pain: morphine sparing effect in orthopedic surgery. Italian Collaborative Group on Propacetamol. Acta Anaesthesiol Scand. 1998;42(3):293–298.
16. Bannwarth B, Netter P, Lapicque F, Gillet P, Pere P, Boccard E et al. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol. 1992;34(1):79–81.
17. Edwards JE, Oldman A, Smith L, et al. Single dose oral aspirin for acute pain. Cochrane Database Syst Rev. 2000;(2):CD002067.
18. Flouvat B, Leneveu A, Fitoussi S, Delhotal-Landes B, Gendron A. Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects. Int J Clin Pharmacol Ther. 2004;42(1):50–57.
19.Internet. 2007. Ref Type: Electronic Citation
20. Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg. 1993;77(5):1048–1056.
21. Mimoz O, Incagnoli P, Josse C, Gillon MC, Kuhlman L, Mirand A et al. Analgesic efficacy and safety of nefopam vs. propacetamol following hepatic resection*. Anaesthesia. 2001;56(6):520–525.
22. Sinatra R. Role of COX-2 inhibitors in the evolution of acute pain management. [Review] [34 refs] Journal of Pain & Symptom Management. 24(1 Suppl):S18–27, 2002 Jul.
23. Van Aken H, Thys L, Veekman L, Buerkle H. Assessing analgesia in single and repeated administrations of propacetamol for postoperative pain: comparison with morphine after dental surgery. Anesth Analg. 2004;98(1):159–165, table.
24. Zhou TJ, Tang J, White PF. Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesth Analg. 2001;92(6):1569–1575.
25. Romsing J, Moiniche S, Dahl JB. Rectal and parenteral paracetamol, and paracetamol in combination with NSAIDs, for postoperative analgesia. Br J Anaesth. 2002;88(2):215–226.
26. Skjelbred P, L++kken P. Paracetamol versus placebo: effects on post-operative course. Eur J Clin Pharmacol. 1979;15(1):27–33.
27. Cobby TF, Crighton IM, Kyriakides K, Hobbs GJ. Rectal paracetamol has a significant morphine-sparing effect after hysterectomy. Br J Anaesth. 1999;83(2):253–256.
28. Hernandez-Palazon J, Tortosa JA, Martinez-Lage JF, Perez-Flores D. Intravenous administration of propacetamol reduces morphine consumption after spinal fusion surgery. Anesth Analg. 2001;92(6):1473–1476.
29. Korpela R, Korvenoja P, Meretoja OA. Morphine-sparing effect of acetaminophen in pediatric day-case surgery. Anesthesiology. 1999;91(2):442–447.
30. Bird HA. Clinical experience with tenoxicam: a review. Scand J Rheumatol Suppl. 1987;65:102–106.
31. Gonzalez JP, Todd PA. Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987;34(3):289–310.
32. Heintz RC. Tenoxicam and renal function. Drug Saf. 1995;12(2):110–119.
33. Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain. 2004;111(3):286–296.
34. Barden J, Edwards JE, McQuay HJ, Moore RA. Single dose oral celecoxib for postoperative pain. Cochrane Database Syst Rev. 2003;(2):CD004233.
35. Cashman JN, Jones RM, Foster JM, Adams AP. Comparison of infusions of morphine and lysine acetyl salicylate for the relief of pain after surgery. Br J Anaesth. 1985;57(3):255–258.
36. Jones RM, Cashman JN, Foster JM, Wedley JR, Adams AP. Comparison of infusions of morphine and lysine acetyl salicylate for the relief of pain following thoracic surgery. Br J Anaesth. 1985;57(3):259–263.
37. Kweekel-de Vries WJ, Spierdijk J, Mattie H, Hermans JM. A new soluble acetylsalicylic acid derivative in the treatment of postoperative pain. Br J Anaesth. 1974;46(2):133–135.
38. Davies NM. Clinical pharmacokinetics of ibuprofen: the first 30 years. Clin Pharmacokinet. 1998;34(2):101–154.
39. Collins SL, Moore RA, McQuay HJ, Wiffen PJ. Oral ibuprofen and diclofenac in post-operative pain: a quantitative systematic review. Eur J Pain. 1998;2(4):285–291.
40. Hodsman NB, Burns J, Blyth A, Kenny GN, McArdle CS, Rotman H. The morphine sparing effects of diclofenac sodium following abdominal surgery. Anaesthesia. 1987;42(9):1005–1008.
41. Campbell WI, Kendrick R, Patterson C. Intravenous diclofenac sodium. Does its administration before operation suppress postoperative pain? Anaesthesia. 1990;45(9):763–766.
42. Moores MA, Wandless JG, Fell D. Paediatric postoperative analgesia. A comparison of rectal diclofenac with caudal bupivacaine after inguinal herniotomy. Anaesthesia. 1990;45(2):156–158.
43. Mason L, Edwards JE, MRMH. Single dose oral naproxen and naproxen sodium for acute postoperative pain. Cochrane Database Syst Rev. 2004; 4.
44. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520–8, 2.
45. Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. [Review] [141 refs] Journal of Neurochemistry. 91(3):521–36, 2004 Nov.
46. ADAPT Research Group. Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clini Trials. 2006;1(7):e33.
47. Vangen O, Doessland S, Lindbaek E. Comparative study of ketorolac and paracetamol/codeine in alleviating pain following gynaecological surgery. J Int Med Res. 1988;16(6):443–451.
48. McQuay HJ, Poppleton P, Carroll D, Summerfield RJ, Bullingham RE, Moore RA. Ketorolac and acetaminophen for orthopedic postoperative pain. Clin Pharmacol Ther. 1986;39(1):89–93.
49. Power I, Noble DW, Douglas E, Spence AA. Comparison of i.m. ketorolac trometamol and morphine sulphate for pain relief after cholecystectomy. Br J Anaesth. 1990;65(4):448–455.
50. Serpell MG, Thomson MF. Comparison of piroxicam with placebo in the management of pain after total hip replacement. Br J Anaesth. 1989;63(3):354–356.
51. Edwards JE, Loke YK, Moore RA, McQuay HJ. Single dose piroxicam for acute postoperative pain. Cochrane Database Syst Rev. 2000;4:CD002762.
52. Hutchison GL, Crofts SL, Gray IG. Preoperative piroxicam for postoperative analgesia in dental surgery. Br J Anaesth. 1990;65(4):500–503.
53. Gonzalez JP, Todd PA. Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. [erratum appears in Drugs 1988 Jan;35(1):preceding 1].
54. Albengres E, Urien S, Barre J, Nguyen P, Bree F, Jolliet P et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity.
55. Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Drugs. 2004;64(11):1231–1261.
56. Chavez ML, DeKorte CJ. Valdecoxib: a review. Clin Ther. 2003;25(3):817–851.
57. Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J. 2005;118(1226):U1755.
58. Jain KK. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs. 2000;9(11):2717–2723.
59. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41(9):1591–1602.
60. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
61. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284(10):1247–1255.
62. Hilmi I, Goh KL. Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.
63. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 1996;111(4):1134–1140.
64. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. [Review] [168 refs] Cancer Detection & Prevention. 28(2):127–42, 2004.
65. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873–884.
66. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. [See comment]. [Review] [36 refs] Journal of the Royal Society of Medicine. 99(3):132–40, 2006 Mar.
67. Rordorf CM, Choi L, Marshall P, Mangold JB. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247–1266.
68. Bannwarth B, Berenbaum F. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Expert Opin Investig Drugs. 2005;14(4):521–533.
69. Matchaba P, Gitton X, Krammer G, et al. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther. 2005;27(8):1196–1214.
70. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6921):81–106.
71. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9):563–572.
72. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296(5567):539–541.
73. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–1102.
74. Huang WF, Hsiao FY, Wen YW, Tsai YW. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Clin Ther. 2006;28(11):1827–1836.
75. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
76.Merck provides preliminary analyses of the completed MEDAL program for ARCOXIA (etoricoxib). www.merck.com. 2006.
77. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1308.
78. Wang D, Wang M, Cheng Y, Fitzgerald GA. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. [erratum appears in Curr Opin Pharmacol. 2005 Oct;5(5):556 Note: Wong, Dairong [corrected to Wang, Dairong]].
79. Hawkey CJ, Skelly MM. Gastrointestinal safety of selective COX-2 inhibitors.
80. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a metaanalytic approach.
81. Bashein G, Nessly ML, Rice AL, Counts RB, Misbach GA. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med. 1991;151(1):89–93.
82. Power I, Chambers WA, Greer IA, Ramage D, Simon E. Platelet function after intramuscular diclofenac. Anaesthesia. 1990;45(11):916–919.
83. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490–496.
84. Krum H, Aw TJ, Liew D, Haas S. Blood pressure effects of COX-2 inhibitors.
85. Aw TJ, Liew D, Tofler GH, Schneider HG, Morel-Kopp MC, Billah B et al. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? J Hypertens. 2006;24(10):1979–1984.
86. Lee A, Cooper MC, Craig JC, Knight JF, Keneally JP. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. Cochrane Database Syst Rev. 2004;(2):CD002765.